Ultragenyx Pharmaceutical Inc.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $673.0M
- Net income
- -$575.0M
- Total assets
- $1.5B
- Market cap
- $2.2B
- Operating margin
- -79.5%
- Net margin
- -85.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $673.0M
- Operating expenses
- $1.2B
- Operating income
- -$535.0M
- Income tax
- $4.0M
- Net income
- -$575.0M
- EPS (basic)
- $-5.83
- EPS (diluted)
- $-5.83
Balance sheet
- Total assets
- $1.5B
- Current assets
- $951.0M
- Total liabilities
- $1.6B
- Current liabilities
- $384.0M
- Shareholders’ equity
- -$80.0M
Cash flow
- Operating cash flow
- -$466.0M
- Investing cash flow
- $236.0M
- Financing cash flow
- $478.0M
- Net cash flow
- $248.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.2B
- EPS (diluted)
- $-5.83
- Shares outstanding
- 99.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 31, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $575.0M in FY2025.
- Revenue grew 148% from FY2020 to FY2025.
- Trading 48% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Ultragenyx Pharmaceutical Inc..
Write a review
News about Ultragenyx Pharmaceutical Inc.
News & sentiment via Polygon.io
